We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-11.11%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.07B
AUM Growth
-$1.54B
Cap. Flow
-$210M
Cap. Flow %
-2.97%
Top 10 Hldgs %
34.72%
Holding
187
New
10
Increased
57
Reduced
82
Closed
15

Top Buys

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$67.9M
2
PFE icon
Pfizer
PFE
+$40.2M
3
CLDX icon
Celldex Therapeutics
CLDX
+$26.9M
4
HRMY icon
Harmony Biosciences
HRMY
+$26M
5
CRL icon
Charles River Laboratories
CRL
+$25.6M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$100M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$81.4M
3
ABBV icon
AbbVie
ABBV
+$47.5M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$47.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$45.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.26%
2 Industrials 0.38%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EL icon
151
Estee Lauder
EL
$28.9B
$343K ﹤0.01%
1,348
– –
LLY icon
152
Eli Lilly
LLY
$1.06T
$314K ﹤0.01%
+969
New +$291K
OPT
153
DELISTED
Opthea Limited American Depositary Shares
OPT
$296K ﹤0.01%
47,000
-1,000
-2% -$6.31K
MCHI icon
154
iShares MSCI China ETF
MCHI
$6.04B
$229K ﹤0.01%
+4,100
New +$210K
SWKS icon
155
Skyworks Solutions
SWKS
$9.1B
$195K ﹤0.01%
2,100
– –
MKTX icon
156
MarketAxess Holdings
MKTX
$4.06B
$169K ﹤0.01%
662
– –
GDXJ icon
157
VanEck Junior Gold Miners ETF
GDXJ
$7.05B
$160K ﹤0.01%
+5,000
New +$206K
ABBV icon
158
AbbVie
ABBV
$454B
$124K ﹤0.01%
808
-310,692
-100% -$47.5M
DLB icon
159
Dolby
DLB
$4.65B
$114K ﹤0.01%
1,600
– –
JMIA
160
Jumia Technologies
JMIA
$734M
$109K ﹤0.01%
18,000
– –
NKTR icon
161
Nektar Therapeutics
NKTR
$2.34B
$109K ﹤0.01%
1,920
-318,640
-99% -$20.1M
MELI icon
162
Mercado Libre
MELI
$91.2B
$108K ﹤0.01%
170
– –
IPGP icon
163
IPG Photonics
IPGP
$4.09B
$99K ﹤0.01%
1,050
– –
AVLR
164
DELISTED
Avalara, Inc.
AVLR
$92K ﹤0.01%
1,300
– –
MRK icon
165
Merck
MRK
$322B
$88K ﹤0.01%
+964
New +$85.5K
ZTS icon
166
Zoetis
ZTS
$31.3B
$86K ﹤0.01%
+503
New +$87K
UTHR icon
167
United Therapeutics
UTHR
$26.4B
$45K ﹤0.01%
+193
New +$39.2K
ASR icon
168
Grupo Aeroportuario del Sureste
ASR
$8.1B
$27K ﹤0.01%
135
– –
EVTC icon
169
Evertec
EVTC
$1.79B
$27K ﹤0.01%
739
– –
EQIX icon
170
Equinix
EQIX
$102B
$26K ﹤0.01%
40
– –
INFY icon
171
Infosys
INFY
$43.2B
$21K ﹤0.01%
1,130
– –
NVST icon
172
Envista
NVST
$4.26B
$19K ﹤0.01%
+484
New +$20.3K
BILI icon
173
Bilibili
BILI
$7.32B
– –
-744
Closed -$19K
BNR
174
Burning Rock Biotech
BNR
$94.4M
– –
-43,887
Closed -$4.08M
BPMC
175
DELISTED
Blueprint Medicines
BPMC
– –
-26,000
Closed -$1.66M
4 5 6
7
8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2022 Portfolio in Review

As of Q2 2022, Bellevue Group held 187 positions worth $7.07B, down 18% from $8.61B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group's Q2 2022 filing shows 10 new, 57 increased, 82 reduced and 15 closed positions. Its largest new stake was Celldex Therapeutics: 925,000 shares worth $24.9M. The largest sale was Elevance Health, an estimated $100M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q2 2022 buy was Celldex Therapeutics: 925,000 shares worth $24.9M.
  • Bellevue Group added most to Intuitive Surgical in Q2 2022, an estimated $67.9M increase.
  • Bellevue Group's biggest Q2 2022 reduction was Elevance Health, cutting an estimated $100M.
  • Bellevue Group fully exited Dentsply Sirona in Q2 2022, selling an estimated $7.83M.
  • Bellevue Group's ten largest holdings make up 35% of its $7.07B portfolio in Q2 2022.
  • Bellevue Group opened 10 new positions and closed 15 in Q2 2022.
  • Bellevue Group's portfolio value fell 18% quarter-over-quarter to $7.07B.

Based on Bellevue Group's 13F filing for Q2 2022, filed 11 Aug 2022.